{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-059026","form_type":"8-K","ticker":"ADGM","cik":"0002006986","company_name":"Adagio Medical Holdings, Inc.","filed_at":"2026-05-12T12:05:25+00:00","discovered_at":"2026-05-12T12:10:00.383265+00:00","generated_at":"2026-05-12T12:17:15.505270+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Adagio Medical reports Q1 2026 net loss $7.0M, cash $12.9M; FULCRUM-VT shows 84% freedom from ICD shock","bullets":["Net loss of $7.0M for Q1 2026 vs $7.7M in Q1 2025; no revenue; R&D expense $2.7M, SG&A $2.5M.","Cash and equivalents of $12.9M as of March 31, 2026; up to $31M additional from milestone-based warrants.","FULCRUM-VT pivotal trial: 84% freedom from ICD shock at 6 months, 2.4% MAE, 72% reduction in antiarrhythmic drug use.","FDA approved IDE to expand FULCRUM-VT trial to evaluate next-generation vCLAS Ultra System.","Successfully completed 13 cases under FDA Expanded Access in patients who failed prior ablation therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-059026","json":"https://secwatch.observer/filing/0001104659-26-059026.json","markdown":"https://secwatch.observer/filing/0001104659-26-059026.md","text":"https://secwatch.observer/filing/0001104659-26-059026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006986/000110465926059026/0001104659-26-059026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006986/000110465926059026/tm2614299d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T12:17:15.505270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb2a08ad04f41bf342d4db7c9c516223918c4e05","claim":"Adagio Medical Holdings, Inc. reported three months ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $7.0 million.","evidence_excerpt":"Net loss for the three months ended March 31, 2026 was $7.0 million, compared to a net loss of $7.7 million for the three months ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000110465926059026/0001104659-26-059026-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2026"},{"label":"Net income","value":"Net loss for the three months ended March 31, 2026 was $7.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}